Gene: LIN28B
Official Full Name: lin-28 homolog Bprovided by HGNC
Gene Summary: The protein encoded by this gene belongs to the lin-28 family, which is characterized by the presence of a cold-shock domain and a pair of CCHC zinc finger domains. This gene is highly expressed in testis, fetal liver, placenta, and in primary human tumors and cancer cell lines. It is negatively regulated by microRNAs that target sites in the 3' UTR, and overexpression of this gene in primary tumors is linked to the repression of let-7 family of microRNAs and derepression of let-7 targets, which facilitates cellular transformation. [provided by RefSeq, Jun 2012]
Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
---|---|---|---|---|---|---|
KO02398 | LIN28B Knockout cell line (HEK293) | Human | LIN28B | 1:3~1:6 | Negative | Online Inquiry |
KO02399 | LIN28B Knockout cell line (A549) | Human | LIN28B | 1:3~1:4 | Negative | Online Inquiry |
LIN28B Gene Knockout Cell Lines are genetically modified cell lines designed to specifically disrupt the expression of the LIN28B gene, a key regulator in developmental biology and stem cell maintenance. This product serves as a powerful research tool for scientists aiming to elucidate the role of LIN28B in various biological processes, including cellular reprogramming, differentiation, and tumorigenesis.
The primary function of LIN28B is to modulate the biogenesis of microRNAs, which are crucial in gene expression regulation. By creating knockout cell lines, researchers can study the effects of LIN28B loss on cellular pathways and identify downstream targets affected by this gene's activity. The mechanism of action involves the disruption of LIN28B's interaction with precursor microRNAs, leading to altered expression profiles that significantly impact cellular fate decisions.
The scientific importance of these cell lines spans multiple research areas, including cancer biology, developmental studies, and regenerative medicine. In clinical settings, understanding LIN28B's role could open new avenues for therapeutic interventions and biomarker development for cancerous tissues where LIN28B overexpression is often implicated.
Compared to alternative models, these knockout cell lines provide a precise and effective means of examining LIN28B's function without the confounding effects that might arise from partial silencing or overexpression systems. Moreover, they enable straightforward experimental setups, enhancing reproducibility in studies centered on gene regulation and its implications in pathophysiology.
Research professionals and clinicians can significantly benefit from this product, as it empowers them to unfold complex gene interactions and drive innovation in personalized medicine strategies. At our company, we pride ourselves on our cutting-edge genetic engineering capabilities and a commitment to delivering state-of-the-art biological products that support advancing scientific knowledge and improve health outcomes.
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.